Adoptive Neoantigen-activated T Cell Transfer Therapy
Tumor immunotherapy is the fourth kind of tumor therapy after surgery, radiotherapy, and chemotherapy. This therapy, which activates and mobilizes the human immune system as a means to control and kill tumor cells, has achieved great success in clinical experiments. Creative Biolabs has been deeply involved in the prevention and treatment of cancer since its inception. For tumor immunotherapy, we have also learned a lot of technology and accumulated rich experience. The method of activating T cells with neoantigen and returning them to the body to treat cancer is a powerful innovation of traditional adoptive cell transfer therapy.
Adoptive cell transfer therapy (ACT)
Adoptive cell transfer therapy (ACT) refers to the isolation of immunocompetent cells from tumor patients, the expansion and functional identification of these cells in vitro, and then infusion back into the patients, so as to achieve the purpose of directly killing tumors or to stimulate the immune response to kill tumor cells. As early as 1985, the United States NCI launched the clinical application of ACT. However, it was later discovered that due to the lack of tumor antigen specificity of this ACT-returned immune cell, it failed to achieve the desired therapeutic effect in the clinic. With the advancement of research, scientists have now clearly realized that the ideal targets for tumor immune cell therapy are tumor-specific antigens that are exclusively expressed on tumor cells. The neoantigens produced are such ideal tumor-specific antigens.
Enhanced ACT - Adoptive Neoantigen-activated T Cell Transfer Therapy
The prediction and identification of such antigens has always been the biggest obstacle hindering the development of this technology. Under the advancement of sequencing technology and the development of artificial intelligence technology, Creative Biolabs took the lead to seize these opportunities and creatively developed AI-based algorithm platform that can accurately predict neoantigen and the platform for in vitro evaluation and verification of predicted neoantigens, both of which have laid a solid foundation for the development of specific ACT. Adoptive neoantigen-activated T cell transfer therapy is an excellent product of these two platforms.
On the basis of prediction, screening, and identification of tumor neoantigens, we preferably select several neoantigens to stimulate and activate T cells in vitro, and amplify them into a large number for patient adoptive infusion. Neoantigen-activated T cells have the ability to specifically kill tumor cells. After entering the human body, they can actively seek and bind to tumor cells, secrete cytotoxic substances, and directly kill tumor cells. Compared with CAR-T technology, neoantigen-activated T-cell adoptive therapy is a strictly personalized treatment paradigm, which has the advantages of wider scope of application, higher treatment efficiency, and fewer side effects. Autologous T cells with innate anti-tumor activity make this therapy more accurate, clear tumor cells in the body more quickly, avoid immune rejection reactions, shun cytokine release syndrome, and are more secure and reliable.
Technical Support for Adoptive Neoantigen-activated T Cell Transfer Therapy
- Tumor neoantigen library covering a large number of high incidence cancers
- NGS sequencing
- AI-aided analysis platform for prediction of tumor neoantigen
- High-efficient neoantigen in vitro evaluation platform
- Peptide synthesis and protein production
- T cell stimulation and activation in vitro
- Massive expansion of activated T cells with normal functions
With the help of sequencing technology, artificial intelligence technology, and rich experience in cancer therapy development, Creative Biolabs has successively developed a platform for predicting neoantigen and a platform for in vitro evaluation of neoantigen. Based on this, we have started the development of various tumor immunotherapy. We can provide various technical services related to this, if you have any needs in this regard, please contact us!
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
